‘Soon, no one will be on Mounjaro’: Slimmers stampede to get hold of experimental ‘Godzilla’ weight loss jab that burns fat faster than ever
Slimmers are rushing to get their hands on a powerful new drug dubbed the ‘Godzilla’ of weight loss jabs—as panic grows over the soaring price of Mounjaro.
Early trials of the drug, retatrutide, suggest it can help people shed a quarter of their body weight in under a year – almost twice as effective as Ozempic.
Unlike other slimming injections, the jab, also manufactured by Eli Lilly, not only suppresses appetite but also speeds up metabolism.
Because it targets three hormones involved in eating and weight regulation, it has been nicknamed ‘triple G’.
The once-weekly injection is still in clinical trials, with phase three results not expected until 2026.
Yet social media users are already claiming to have sourced the drug on the black market, boasting of losing more than three stone in just months.
Others have scoured forums desperate to find supplies. One Reddit user wrote: ‘I’m thinking of switching to black market reta. Lilly forces me. I can’t afford the £300 price [of Mounjaro].’
Another admitted: ‘Seeing a lot on TikTok about retatrutide, especially bodybuilders using it to get ripped.’
Social media users are already claiming to have sourced the drug on the black market, boasting of losing more than three stone in just months
Eli Lilly’s trial results, published in the New England Journal of Medicine last year, followed 338 overweight and obese adults for 48 weeks. Those taking the highest dose of the weekly injection – 12 mg – shed nearly 25 percent of their bodyweight by the study’s end
A TikTok user already claiming to inject it, added: ‘Two years from now, nobody will be using Mounjaro anymore.’
The scramble comes after Eli Lilly confirmed that from September the cost of Mounjaro in the UK will soar – with the highest dose jumping 170 per cent, from £122 to £330 a month.
Even mid-range doses such as 5mg will nearly double to £180. The jab is currently prescribed to around 90 per cent of Britons using weight-loss injections.
Health experts have urged people not to be tempted by unapproved supplies of retatrutide, warning that most are counterfeit and could be dangerous.
Dr Helen Wall said: ‘The issue is, we don’t really know what the risks are and we don’t know the dosing either.
‘It’s certainly not just a stronger version of Ozempic or Mounjaro. It’s working on a different pathway, so that needs exploration in terms of safety and side effects.’
Eli Lilly also issued a stark warning. A spokesperson said: ‘Retatrutide is an investigational molecule that Lilly is studying for the treatment of obesity—it is in phase 3 clinical trials and is not available to patients outside of these trials.
‘Any product falsely representing itself as a Lilly investigational product not yet approved… may expose patients to potentially serious health risks.’
Health experts have urged people not to be tempted by unapproved supplies of retatrutide, warning that most are counterfeit and could be dangerous
Eli Lilly also issued a stark warning. A spokesperson said: ‘Retatrutide is an investigational molecule that Lilly is studying for the treatment of obesity—it is in phase 3 clinical trials and is not available to patients outside of these trials’
Pharmacists say the looming Mounjaro price hike could drive more people towards the black market.
Robert Bradshaw, superintendent pharmacist at Oxford Online Pharmacy, told the Mail: ‘The bigger concern is that this sharp price increase could fuel the expansion of the weight-loss jab black market.
‘Unlicensed and illegal jabs have circulated since weight-loss injections first became popular, often being sold via social media and by unlicensed individuals with no regulation.’
Last year this website revealed counterfeit versions of the drug were already on sale in Britain for as little as £2 a shot.
Chinese firms were even offering samples for 80p a dose, labelled as ‘research only’ and ‘not for human consumption’ in a bid to dodge regulators.
Trial results so far have shown striking weight-loss figures.
In one study, women on retatrutide lost an average of 28.5 per cent of their body weight in 48 weeks, while men lost 21.2 per cent.
More obese participants lost 26.5 per cent, and unusually every single participant shed at least five per cent of their body weight.
Side effects were similar to other GLP-1 drugs, including nausea, diarrhoea and constipation.
By comparison, Ozempic typically results in up to 15 per cent weight loss over 68 weeks, while Mounjaro has been shown to deliver up to 22.5 per cent over 72 weeks.
Despite the hype, experts stress that retatrutide remains experimental and years away from approval.
Until then, desperate patients sourcing it online may be risking far more than their waistlines.
